[1]袁少勇,姜玲,潘华.胶质母细胞瘤病人血清sLRIG3水平检测的临床意义[J].中国临床神经外科杂志,2024,29(08):469-472486.[doi:10.13798/j.issn.1009-153X.2024.08.006]
　YUAN Shao-yong,JIANG Ling,PAN Hua.Clinical significance of serum sLRIG3 levels in predicting prognosis of patients with glioblastoma[J].,2024,29(08):469-472486.[doi:10.13798/j.issn.1009-153X.2024.08.006]
点击复制

胶质母细胞瘤病人血清sLRIG3水平检测的临床意义()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年08期
页码:
469-472486
栏目:
论著
出版日期:
2024-08-30

文章信息/Info

Title:
Clinical significance of serum sLRIG3 levels in predicting prognosis of patients with glioblastoma
文章编号:
1009-153X（2024）08-0469-04
作者:
袁少勇; 姜玲; 潘华
266000山东，康复大学青岛中心医院（青岛市中心医院）神经外二科（袁少勇、姜玲、潘华）
Author(s):
YUAN Shao-yong;  JIANG Ling;  PAN Hua
Second Department of Neurosurgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao 266000, China
关键词:
胶质母细胞瘤; 可溶性人类富含亮氨酸重复序列和免疫球蛋白样结构域3（sLRIG3）; 血清; 生存预后
Keywords:
Glioblastoma multiforme;  Soluble human leucine-rich repeats and immunoglobulin-like domain 3 (sLRIG3);  Serum;  Survival prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2024.08.006
文献标志码:
A
摘要:
目的 探讨血清可溶性人类富含亮氨酸重复序列和免疫球蛋白样结构域3（sLRIG3）预测胶质母细胞瘤（GBM）预后的价值。方法 2019年9月至2022年12月前瞻性收集60例GBM的肿瘤样本和血清样本，另外收集同期健康60例的血清样本作为对照，采用酶联免疫吸附法测定血清sLRIG3水平，采用免疫组织化学染色检测肿瘤组织LRIG3的表达。GBM病人随访至死亡或2023年12月31日，记录无进展生存期（PFS）和总生存期（OS）。结果 GBM病人血清sLRIG3水平[（2.84±0.89）ng/ml]显著低于对照组[（4.62±2.16）ng/ml；P<0.001]。免疫组化染色显示，LRIG3高表达38例（63.33%），低表达22例。GBM组织LRIG3高表达病人血清sLRIG3水平[（1.98±0.33）ng/ml]明显低于低表达病人[（3.33±0.72）ng/ml；P<0.001）。 60例GBM病人随访12~48个月，中位PFS为12.50（IQR：8.78~21.30个月）；中位OS为16.40（IQR：10.13~24.70个月）。肿瘤进展GBM病人血清sLRIG3水平[（2.74±0.84）ng/ml]明显低于无肿瘤进展病人[（3.92±0.72）ng/ml；P=0.004]。死亡GBM病人血清sLRIG3水平[（2.42±0.71）ng/ml）明显低于存活病人[（3.47±0.76）ng/ml；P<0.001]。多因素Cox比例回归风险模型分析显示，血清sLRIG3水平降低是GBM病人死亡的独立预测因素。Kaplan-Meier曲线分析显示，血清sLRIG3水平<3.23 ng/ml的GBM病人的中位OS明显缩短（P=0.016）。结论 GBM病人血清sLRIG3显著降低，与病人的不良预后密切相关。
Abstract:
Objective To investigate the value of serum soluble human leucine-rich repeats and immunoglobulin-like domain 3 (sLRIG3) in predicting prognosis of patients with glioblastoma multiforme (GBM). Methods A total of 60 patients with GBM were prospectively enrolled from September 2019 to December 2022, and their tumor tissues and serum samples were collected for analysis. Additionally, serum samples from 60 healthy individuals served as control. The serum sLRIG3 level was tested using enzyme-linked immunosorbent assay (ELISA), and LRIG3 expression in tumor tissues was assessed by immunohistochemistry. The follow-up period for GBM patients extended until either death or December 31, 2023, during which progression-free survival (PFS) and overall survival (OS) data were recorded. Results The mean serum sLRIG3 level in GBM patients (2.84±0.89 ng/ml) was significantly lower than that (4.62±2.16 ng/ml) in the control group (P<0.001). Immunohistochemical staining revealed that high-expression of LRIG3 was observed in 38 GBM patients (63.33%), while low-expression in the remaining 22 GBM patients. The serum sLRIG3 levels in GBM patients with high-expression of LRIG3 (1.98±0.33 ng/ml) was significantly lower than that (3.33±0.72 ng/ml) in GBM patients with low-expression of LRIG3 (P<0.001). The 60 GBM patients were followed up for 12~48 months. The median PFS was 12.50 months (IQR: 8.78~21.30 months), and the median OS was 16.40 months (IQR: 10.13~24.70 months). The serum sLRIG3 level of GBM patients with tumor progression (2.74±0.84 ng/ml) was significantly lower than that (3.92±0.72 ng/ml) of patients without tumor progression (P=0.004). The serum sLRIG3 level of dead GBM patients (2.42±0.71 ng/ml) was significantly lower than that (3.47±0.76 ng/ml) of surviving patients (P<0.001). The multivariate Cox proportional hazards regression model analysis demonstrated that a decreased serum sLRIG3 level was an independent predictive factor for the death of GBM patients. The Kaplan-Meier curve analysis indicated that the median OS of GBM patients with a serum sLRIG3 level < 3.23 ng/ml was significantly shortened (P=0.016). Conclusion The serum sLRIG3 level of GBM patients is significantly decreased and is closely associated with the poor prognosis of the patients.

参考文献/References:

[1]JACOB F, SALINAS RD, ZHANG DY, et al. A patient-derived glio-blastoma organoid model and biobank recapitulates inter-and intra-tumoral heterogeneity[J]. Cell, 2020, 180(1): 188-204.
[2]LUO C, SONG K, WU S, et al. The prognosis of glioblastoma: a large, multifactorial study[J]. Br J Neurosurg, 2021, 35(5): 555-561.
[3]LI Y, WANG W, HOU X, et al. Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate micro-environment and suppress tumor growth[J]. Cell Death Dis, 2023, 14(1): 28-42.
[4]CHENG F, ZHANG P, XIAO Q, et al. The prognostic and therapeutic potential of LRIG3 and soluble LRIG3 in glioblastoma[J]. Front Oncol, 2019, 9: 447-463.
[5]ZHANG J, HUANG CH, MAO H. Expression of KDELR2 in glioma tissues and its clinical significance: an analysis based on tissue microarray technology[J]. Chin J Clin Neurosurg, 2024, 29(3): 151-156, 176. 张　娇，黄纯海，毛　辉. KDELR2在胶质瘤中的表达及临床意义：基于组织芯片技术分析[J]. 中国临床神经外科杂志，2024，29（3）：151-156，176.
[6]KANG X, WANG YL, WANG C, et al. Efficacy of carboplatin combined with etoposide in the treatment of secondary/recurrent high-grade glioma[J]. J Neurosci Mental Health, 2023, 23(7): 490-496. 康　勋，王亚丽，王　策，等. 卡铂联合依托泊苷治疗继发/复发高级别胶质瘤的疗效分析[J]. 神经疾病与精神卫生，2023，23（7）：490-496.
[7]LINHARES P, CARVALHO B, VAZ R, et al. Glioblastoma: is there any blood biomarker with true clinical relevance[J]. Int J Mol Sci, 2020, 21(16): 5809-5824.
[8]ABDULLAH A, HERDENBERG C, HEDMAN H. Ligand-specific regulation of transforming growth factor beta superfamily factors by leucine-rich repeats and immunoglobulin-like domains proteins [J]. PLoS One, 2023, 18(8): e0289726-e0289740.
[9]HERDENBERG C, MUTIE PM, BILLING O, et al. LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes[J]. Commun Biol, 2021, 4(1): 90-104.
[10]REN S, LIU WF, SHANG JX. Expression of miR-196a/LRIG3 in colorectal cancer tissues and its effects on proliferation and invasion of HCT116 Cells[J]. Med Pharmac J Chin PLA, 2021, 33(11): 22-26. 任　松，刘雯菲，尚锦秀. miR-196a/LRIG3在结直肠癌组织中的表达及对HCT116细胞增殖、侵袭的影响[J]. 解放军医药杂志，2021，33（11）：22-26.
[11]RAZUMOVA Z, ODA H, GOVOROV I, et al. The prognostic role of LRIG proteins in endometrial cancer[J]. Cancers (Basel), 2021, 13 (6): 1361-1372.
[12]M SERAG EL-DIEN M, FATHY MAHMOUD S, ALHANAFY AM, et al. Prognostic significance of LRIG2 and LRIG3 proteins in uro-thelial bladder carcinoma[J]. J Immunoassay Immunochem, 2022, 43(3): 308-332.
[13]MAO F, WANG B, XIAO Q, et al. LRIG proteins in glioma: functional roles, molecular mechanisms, and potential clinical implications[J]. J Neurol Sci, 2017, 383: 56-60.
[14]GUO D, YANG H, GUO Y, et al. LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor[J]. J Neurol Sci, 2015, 350(1-2): 61-68.
[15]PENG C, CHEN H, LI Y, et al. LRIG3 suppresses angiogenesis by regulating the PI3K/AKT/VEGFA signaling pathway in glioma[J]. Front Oncol, 2021, 11: 621154-621164.
[16]GUO G, GONG K, BECKLEY N, et al. EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation[J]. Nat Cell Biol, 2022, 24(8): 1291-1305.
[17]PENG K, ZHOU CG, XIA RP, et al. Overexpression of LRIG3 on cell biological behaviors of human neuroblastoma cell line SK-N-MC[J]. Chin J Clin Neurosurg, 2020, 25(7): 458-461. 彭　琨，周崇高，夏仁鹏，等. LRIG3基因过表达对人神经母细胞瘤细胞系SK-N-MC细胞生物学行为的影响[J]. 中国临床神经外科杂志，2020，25（7）：458-461.
[18]QI Y, CHANG L, LI H, et al. Over-expression of LRIG3 suppresses growth and invasion of bladder cancer cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(1): 111-116.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(08):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(08):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(08):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(08):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(08):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(08):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(08):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(08):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

备注/Memo

备注/Memo:
（2024-02-19收稿，2024-05-16修回）
基金项目：山东省自然科学基金（ZR2016HL44）
更新日期/Last Update: 2024-08-30